7Baggers
 Jefferies initiates coverage on ALX Oncology stock with Buy rating  Investing.com Thu, 13 Nov 2025 11:13:07 GMT
 alx oncology earnings call: optimism amid challenges  TipRanks Sun, 09 Nov 2025 01:43:18 GMT
 Alx Oncology Earnings Call: Optimism Amid Challenges  TipRanks Sat, 08 Nov 2025 08:00:00 GMT
 alx oncology reports promising q3 2025 results  TipRanks Sat, 08 Nov 2025 04:43:38 GMT
 ALX Oncology Cuts Losses And Earns Wall Street’s Approval  Finimize Fri, 07 Nov 2025 20:48:55 GMT
 Earnings call transcript: ALX Oncology Q3 2025 shows promising drug progress  Investing.com Nigeria Fri, 07 Nov 2025 15:13:47 GMT
 alx oncology q3 2025 earnings call transcript  MarketBeat Fri, 07 Nov 2025 14:48:45 GMT
 alxo's financial outlook: funding secured into 2027  GuruFocus Fri, 07 Nov 2025 14:28:25 GMT
 alxo advances in cancer trials with promising early results  GuruFocus Fri, 07 Nov 2025 14:17:38 GMT
 ALX Oncology sees cash runway into 1Q27  TipRanks Fri, 07 Nov 2025 14:03:08 GMT
 alx oncology reports q3 eps (41c), consensus (37c)  TipRanks Fri, 07 Nov 2025 14:01:55 GMT
 ALX Oncology Q3 net loss narrows as R&D costs drop  TradingView Fri, 07 Nov 2025 13:23:30 GMT
 ALX Oncology Reports Promising Q3 2025 Results  TipRanks Fri, 07 Nov 2025 08:00:00 GMT
 pivotal week ahead for alx oncology investors  AD HOC NEWS Sat, 01 Nov 2025 08:21:03 GMT
 alx oncology (alxo) expected to announce earnings on thursday  MarketBeat Fri, 31 Oct 2025 10:20:15 GMT
 alx-2004 exerts antitumor activity in egfr-expressing tumors  BioWorld MedTech Thu, 30 Oct 2025 18:14:51 GMT
 ALX Oncology to Report Third Quarter 2025 Financial Results  GlobeNewswire Thu, 30 Oct 2025 07:00:00 GMT

ALX Oncology Holdings Inc
(NASDAQ:ALXO) 

ALXO stock logo

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the ...

Founded: 2015
Full Time Employees: 17
CEO: Jaume Pons  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends